BSE:522275 22 December 2025

May 14, 2026, 2:53 AM EDT. Nanjing Leads Biolabs, a clinical-stage biotech focused on antibody drugs, saw its shares drop 8% in one day and 12% over the past week despite a strong 3-month and year-to-date rally. The stock closed at HK$69.40, valuing the company at roughly HK$13.8 billion. Recent declines reflect investor caution over growth prospects and clinical pipeline risks. The discounted cash flow (DCF) model estimates an intrinsic value of HK$18.62 per share, far below current prices, suggesting the stock is trading at a steep premium. As the company posts revenue growth but still reports a net loss of CN¥211.419 million, further volatility is likely. Investors should watch pipeline progress closely, given the risk that elevated losses and delayed commercialization could trigger a correction.